Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma
Fuente:
Redalyc
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Artículo científico |
| Lenguaje: | en |
| Publicado: |
Sociedade Portuguesa de Pneumologia
2015
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1876486764585025536 |
|---|---|
| author | M. Pereira Barbosa |
| author_facet | M. Pereira Barbosa |
| contents | Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma M. Pereira Barbosa A. Bugalho de Almeida C. Pereira C.-W. Chen P. Georgiou G. Peachey eXpeRience study group Medicina Anti Omalizumab Exacerbations Asthma control Allergic asthma Introduction: The real life effectiveness, safety and the use of omalizumab for Portuguese patients with uncontrolled persistent allergic asthma are not sufficiently well known. The objective of this report was to make an evaluation, in a post-marketing, non-interventional, observational registry, of the Portuguese population included in the eXpeRience study. Methods: The methods used in this report are the same as the global eXpeRience ones, applied to a Portuguese sub-population. Patients with uncontrolled allergic asthma who had started omalizumab within the previous 15 weeks were enrolled and received omalizumab add-on therapy for 24 months. The physicians’ global evaluation of treatment effectiveness (GETE), asthma symptoms and control (ACT score), quality of life (mini-AQLQ score), exacerbations, and serious adverse events (SAE) were reported. Results: Of the 943 patients recruited in the eXpeRience registry, 62 patients were from Portugal. 62.1% of them were observed to be responders with good/excellent GETE assessment at Week 16. Clinically meaningful improvements in asthma control (ACT score) and quality of life (mini-AQLQ score) were observed with omalizumab therapy at Months 12 (mean change: +7.7 [n = 35]; +2.1 [n = 20], respectively) and 24 (mean change: +7.0 [n = 26]; +2.7 [n = 13], respectively). Asthma symptoms and rescue medication usage were reduced to ≤1 day/week at Month 24 from a baseline of ≥3.5 days/week. The proportion of patients with no clinically significant exacerbations increased from 6.5% during pre-treatment (n = 62) to 50% at Month 12 (n = 54) and 60% at Month 24 (n = 45). 2015 artículo científico 0873-2159 https://www.redalyc.org/articulo.oa?id=169737162008 en http://www.redalyc.org/revista.oa?id=1697 Revista Portuguesa de Pneumología application/pdf Sociedade Portuguesa de Pneumologia Revista Portuguesa de Pneumología (Portugal) Num.3 Vol.21 |
| format | Artículo científico |
| id | redalyc_169737162008 |
| institution | Redalyc |
| language | en |
| publishDate | 2015 |
| publisher | Sociedade Portuguesa de Pneumologia |
| spellingShingle | Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma M. Pereira Barbosa Medicina Anti Omalizumab Exacerbations Asthma control Allergic asthma Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma M. Pereira Barbosa A. Bugalho de Almeida C. Pereira C.-W. Chen P. Georgiou G. Peachey eXpeRience study group Medicina Anti Omalizumab Exacerbations Asthma control Allergic asthma Introduction: The real life effectiveness, safety and the use of omalizumab for Portuguese patients with uncontrolled persistent allergic asthma are not sufficiently well known. The objective of this report was to make an evaluation, in a post-marketing, non-interventional, observational registry, of the Portuguese population included in the eXpeRience study. Methods: The methods used in this report are the same as the global eXpeRience ones, applied to a Portuguese sub-population. Patients with uncontrolled allergic asthma who had started omalizumab within the previous 15 weeks were enrolled and received omalizumab add-on therapy for 24 months. The physicians’ global evaluation of treatment effectiveness (GETE), asthma symptoms and control (ACT score), quality of life (mini-AQLQ score), exacerbations, and serious adverse events (SAE) were reported. Results: Of the 943 patients recruited in the eXpeRience registry, 62 patients were from Portugal. 62.1% of them were observed to be responders with good/excellent GETE assessment at Week 16. Clinically meaningful improvements in asthma control (ACT score) and quality of life (mini-AQLQ score) were observed with omalizumab therapy at Months 12 (mean change: +7.7 [n = 35]; +2.1 [n = 20], respectively) and 24 (mean change: +7.0 [n = 26]; +2.7 [n = 13], respectively). Asthma symptoms and rescue medication usage were reduced to ≤1 day/week at Month 24 from a baseline of ≥3.5 days/week. The proportion of patients with no clinically significant exacerbations increased from 6.5% during pre-treatment (n = 62) to 50% at Month 12 (n = 54) and 60% at Month 24 (n = 45). 2015 artículo científico 0873-2159 https://www.redalyc.org/articulo.oa?id=169737162008 en http://www.redalyc.org/revista.oa?id=1697 Revista Portuguesa de Pneumología application/pdf Sociedade Portuguesa de Pneumologia Revista Portuguesa de Pneumología (Portugal) Num.3 Vol.21 |
| title | Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma |
| topic | Medicina Anti Omalizumab Exacerbations Asthma control Allergic asthma |
| url | https://www.redalyc.org/articulo.oa?id=169737162008 |